Skip to main content
. 2022 Apr 3;14(4):e23785. doi: 10.7759/cureus.23785

Figure 2. Trends of prohemostatic and antihemostatic drivers in the different phases of hemostasis in chronic liver disease patients.

Figure 2

ADAMTS 13 denotes disintegrin and metalloprotease with thrombospondin type 1 motif 13 

PAI: plasminogen activator inhibitor; TAFI: thrombin-activatable fibrinolysis inhibitor; tPA: tissue plasminogen activator